View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 28, 2019updated 25 Nov 2021 10:04am

Eidos Therapeutics starts Phase III trial of AG10 in ATTR-CM

Eidos Therapeutics has commenced a pivotal Phase III clinical trial of its investigational small molecule AG10 for the treatment of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).

Eidos Therapeutics has commenced a pivotal Phase III clinical trial of its investigational small molecule AG10 for the treatment of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).

ATTR is caused by tetrameric transthyretin (TTR) destabilisation due to inherited mutations or aging. AG10 is designed to stabilise TTR and prevent the molecular events leading to amyloidosis (ATTR).

The global Phase III trial is dubbed ATTRibute-CM and will compare 800mg AG10 with placebo in a total of 510 patients suffering from symptomatic ATTR-CM associated with either wild-type or mutant TTR.

ATTRibute-CM will include two potentially registrational primary endpoints.

“The trial is designed to evaluate preservation of function and quality of life on an accelerated timeframe.”

Part A will measure the benefit of a change from baseline in six-minute walk distance (6MWD) at 12 months, while Part B will evaluate the decrease in all-cause mortality and the frequency of cardiovascular-related hospitalisations at 30 months.

The trial will also involve secondary endpoints such as quality of life assessment, safety parameters, serum TTR levels, and TTR stabilisation.

Eidos Therapeutics president and chief medical officer Jonathan Fox said: “ATTRibute-CM aims to generate registrational evidence that AG10 provides meaningful benefit to ATTR-CM patients.

“The trial is designed to evaluate preservation of function and quality of life on an accelerated timeframe in addition to evaluating longer-term benefit on mortality and cardiovascular-related hospitalisations.

Positive data from the trial is expected to support the approval of AG10 in ATTR-CM treatment.

A previous Phase II trial involving symptomatic ATTR-CM patients demonstrated that AG10 was generally well-tolerated and significantly increased serum transthyretin in a dose-dependent manner.

Participants who received AG10 experienced normal serum transthyretin levels within 28 days of treatment.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena